Healthcare Active Runners: Express Scripts Holding (NASDAQ:ESRX), Zogenix (NASDAQ:ZGNX), Boston Scientific (NYSE:BSX), Abbott Laboratories (NYSE:ABT)

Gilead Sciences GILD NASDAQ:GILD

Express Scripts (NASDAQ:ESRX) announced that it has been recognized by the Ethisphere Institute, an independent center of research promoting best practices in corporate ethics and governance, as a 2014 World’s Most Ethical Company Express Scripts Holding Company (NASDAQ:ESRX) stock performance was -1.19% in last session and finished the day at $76.99. Traded volume was 13,770,673 million shares in the last session and the average volume of the stock remained 4.94 million shares. The beta of the stock remained 1.29. Express Scripts Holding Company (NASDAQ:ESRX) insider ownership is 0.20%.

Zogenix Inc. (NASDAQ:ZGNX) has traded like a company that is about to implode. Its highly controversial Zohydro has been getting inquiries into how it was approved for marketing despite an FDA panel being against the recommendation. Zogenix, Inc. (NASDAQ:ZGNX) dropped -4.12 percent to $3.26 yesterday on volume of 14.62 million shares. The intra-day range of the stock was $3.16 to $3.45. Zogenix, Inc. (NASDAQ:ZGNX) has a market capitalization of $454.90 million.

Boston Scientific Corp. (NYSE:BSX) EVP Michael Phalen sold 13,500 shares of the stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $13.05, for a total value of $176,175.00. Boston Scientific Corporation (NYSE:BSX)’s stock on Mar 21, 2014 reported a decrease of -2.14 % to the closing price of $12.82. Its fifty two weeks range is $7.07 -$14.08. The total market capitalization recorded $16.98 billion. The overall volume in the last trading session was 14,658,947 million shares. In its share capital, Boston Scientific Corporation (NYSE:BSX) has 1.33 million outstanding shares.

Abbott Laboratories (NYSE:ABT) had its neutral rating reissued by analysts at Zacks. They currently have a $41.00 price target on the stock. Zacks’ analyst wrote, “Abbott reported fourth quarter 2013 earnings of $0.58 per share, in line with the Zacks Consensus Estimate. Sales of $5.6 billion were short of the Zacks Consensus Estimate. On Friday, shares of Abbott Laboratories (NYSE:ABT) dropped -1.23% to close the day at $38.39. Company return on investment (ROI) is 8.00% and its monthly performance is recorded as -1.44%. Abbott Laboratories (NYSE:ABT) quarterly revenue growth is 1.27%.

Signup for free to be the first to receive exclusive free links. Now in your mailbox!
Join over 15,000 subscribers
Send me links

Your information will not be shared to anyone